University of California San Francisco
Give to UCSFNow in its sixth year, the Best Global Universities rankings focus on schools’ academic research and reputation.
Research team has detected the immunological remnants of a common seasonal virus in spinal fluid from dozens of patients diagnosed with acute flaccid myelitis (AFM). The findings provide the clearest evidence to date that AFM is caused by an enterovirus (EV) that invades and impairs the central nervous system.
The UCSF scientists who identified the two known human genes that promote “natural short sleep” have now discovered a third, and it’s also the first gene that’s ever been shown to prevent the memory deficits that normally accompany sleep deprivation.
International team of researchers report progress in using stem cells to develop new therapies for Pelizaeus-Merzbacher disease, a rare genetic condition affecting boys that can be fatal before 10 years of age.
Julius received the prize “for discovering molecules, cells, and mechanisms underlying pain sensation.”
Researchers discovered a scorpion toxin that targets the “wasabi receptor,” which they think it can be used as a tool for studying chronic pain and inflammation, and may eventually lead to the development of new kinds of non-opioid pain relievers.
Study shows that the adult-to-iPSC conversion process can mutate DNA found in mitochondria, causing mice and humans to reject iPSCs, and stem cell transplants more generally.
In a paper researchers describe a technique that uses a special version of CRISPR developed at UCSF to systematically alter the activity of genes in human neurons generated from stem cells, the first successful merger of stem cell-derived cell types and CRISPR screening technologies.
Researchers devised “smart” cells that behave like tiny autonomous robots which may be used to detect damage and disease, and deliver help at just the right time and in just the right amount.
A new study from UCSF suggests that a protein found in the common bullfrog may one day be used to detect and neutralize a poisonous compound produced by red tides and other harmful algal blooms.
A two-week course of an experimental immunotherapy called teplizumab dramatically reduced type 1 diabetes (T1D) diagnosis rates in people at high risk for the disease, according to newly published